Background Current evidence supports the efficacy of prolonged dual antiplatelet treatment
(DAPT) for patients at high-ischemic risk and low bleeding risk as well as the efficacy and …

Background The use of a short duration of dual antiplatelet therapy (DAPT) has become
increasingly common in patients with high bleeding risk (HBR). This study aimed to evaluate …

Clinical practice guidelines recommend extending dual antiplatelet therapy (DAPT) beyond
1 year after acute coronary syndrome (ACS) in patients with high ischemic risk and without …

Background Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant
ischemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …

Introduction Real‐world, country‐specific studies of dual antiplatelet therapy (DAPT)
duration among survivors of acute coronary syndrome (ACS) are important for improving …

Background In current clinical practice, controversy remains regarding the clinical benefits of
prolonged dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients …

Background Randomized controlled trials have shown a reduced risk of ischemic events
and an increased risk of bleeding in patients treated with prolonged dual anti-platelet …

Aim Guidelines recommend 12-months DAPT as standard therapy following acute coronary
syndrome (ACS) but shorter duration DAPT in high bleeding risk patients. Ischaemic and …

Abstract Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant
ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …

Objective: It remains controversial whether to extend the course of dual antiplatelet therapy
(DAPT) after percutaneous coronary intervention (PCI). We conducted a study to investigate …